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By Susan I. Finkelstein
Cancer. The Big “C.” The very name invari-
ably conjures fear. According to recent statistics,
one of every three Americans will face a diag-
nosis of cancer. But what many people don’t
know is that pets get cancer, too—and in ever-
greater numbers. Like people, more companion
animals are living longer due to better quality
of life, preventive medical care, and vaccina-
tions—and longer life translates into an
increased risk of developing cancer. Over 10
percent of dogs and slightly fewer cats develop
the disease each year, roughly the same rate as
humans. Half of veterinary patients over 10
years of age will get cancer, and about one-
quarter will die from it.
Enter the Oncology Service at the Ryan
Hospital, dedicated to providing compassion-
ate, efficient, state-of-the-art care to dogs and
cats with cancer. Board-certified veterinary and
radiation oncologists, residents in training for
certification, and oncology nurses all are part of
the Ryan team, which handled an estimated
2,800 patient visits last year. Standard cancer
treatments similar to those used in people
(chemotherapy, radiation therapy, and surgery)
may prolong survival and provide an excellent
quality of life in many dogs and cats with can-
cer. Unlike with people, though, the goal of
treating cancer in companion animals is not
necessarily eradicating the tumors, but improv-
ing the animal’s overall comfort level.
Up Close and Personal
Pat Thatcher, associate director of Penn’s
Office of Learning Resources, recently had a
very personal experience with the Oncology
Service: Archie the cat, her wise and devoted
companion of 10 years, was diagnosed with
lymphoma after two months of intermittent
severe vomiting and diarrhea. After much dis-
cussion with Oncology clinicians, Pat decided
to pursue an aggressive course of chemo-
therapy. Archie and Pat were both put in the
“stubborn fighter” category, and Beth Overley,
V’00, lecturer in oncology, and Jen Baez,V’92,
assistant professor of oncology, felt that
chemotherapy could conservatively extend
Archie’s life and increase his quality of life for
six to nine months, possibly a year. Nineteen
months later—a period that included a remis-
sion in which he did not require intravenous
chemotherapy—Archie’s previously low-grade
heart murmur seemed to worsen, and ultimate-
ly heart problems caused his death. He was in a
treatment hiatus when he died, and technically
still in a form of cancer remission.
“The entire Oncology staff, including all the
interns who helped us throughout Archie’s 19-
month chemotherapy saga, were wonderful,”
recalls Pat. “In addition to excellent veterinary
clinical training and practice, they had pro-
found ‘people sense’ and were compassionate
and responsive. . . . I have to say that the whole
department had an infectious, positive attitude.
Archie and I both took on their positive
approach, and neither of us second-guessed or
regretted our association with Oncology and
chemo, even when the going got very tough.”
In February 2003, together with four others,
Pat founded the Pets with Cancer Lifeline, a
support system for people whose pets are being
treated at the Ryan Hospital’s Oncology Service.
On its website, <www.dogdoggiedog.com/
PetswithCancer.htm>, the grassroots group
describes itself as a “network to provide infor-
mation and support to the families of the
newest Oncology patients who have practical
questions about pets living with cancer, or sim-
ply want to talk with someone whose pet has
received a similar diagnosis.” Along with stories
and photos of pets who fought cancer—and
beat or succumbed to it—are names and email
addresses for those wishing to contact one of
the cofounders. “We can tell you that our pets
have done well in treatment, with excellent
quality of life and minimal side effects. We
know that Ryan’s Oncology Service provides
exceptional treatment. . . . We know they truly
care about each and every patient.”
As Archie’s case suggests, some animals may
need more aggressive treatment than the stan-
dard chemotherapy, surgery, or traditional radi-
ation allows. Penn’s radiation equipment, now
almost 40 years old, is no longer the most effec-
tive or humane cancer-treating technology
available. As a result, each year the Hospital is
forced to turn away or refer hundreds of cancer
patients elsewhere due to lack of appropriate
equipment. To ameliorate the situation, the
School has launched a fundraising campaign to
convert its 8,000-square-foot parking garage
into a comprehensive Radiation Therapy and
Imaging Facility that will house a linear acceler-
ator (high-energy radiation), an MRI suite, and
nuclear scintigraphy (bone scan) equipment—
making the School the major academic referral
center in the eastern United States for diagnostic
imaging and treatment of companion animals.
The Research
Healing, though, is only one part of Oncolo-
gy at Penn Veterinary Medicine; information
gleaned from clinical research with veterinary
patients provides valuable knowledge that can
improve the understanding and treatment of
both human and animal cancers. Because many
of these trials are funded by grants, pet owners
often are not charged or pay just a part of the
cost of the animal’s participation.
“Clinical trials involving companion ani-
mals are often the stepping stone to clinical tri-
als in humans,” notes Dr. Baez. The Oncology
Service currently is involved in many clinical
trials, a partial list of which appears below.
Feline cancer cachexia: The goal of this
study is to determine the incidence of cachexia
(weight loss, wasting of muscle, and general
debility) among cats presented to the Oncology
Service at the Ryan Hospital and to compare
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the incidence of cachexia in the cats with and
without tumors that are being treated here.
Canine hemangiosarcoma: Clinicians are
examining the efficacy and toxicity of the
chemotherapy drug Doxil following surgery on
dogs with hemangiosarcoma, an aggressive
malignancy of blood vessels and the lining of
blood-filled spaces, most commonly the spleen.
Feline mammary tumor: This study evalu-
ates the role that reproductive/hormonal status
plays in the incidence of breast cancer in female
cats. In human and dog breast cancers, studies
show that reproductive/hormonal status is
important in the prognosis, prevention, and
treatment of disease. In dogs, a study similar
showed an increased risk of breast cancer corre-
lated with the age at which a dog was spayed. A
more recent study also showed that dogs spayed
around the time of diagnosis of mammary can-
cer enjoyed potentially improved survival rates
as well.
Canine melanoma: This study aims to
determine if the addition of chemotherapy to
the treatment of dogs with early-stage oral
melanoma (skin cancer) will improve survival
rates. Previous studies have evaluated treat-
ments of the primary tumor but have not
addressed treatment and prevention of micro-
scopic secondary tumors. Even with excellent
local treatment and no evidence of the spread
of cancer at diagnosis, most diagnosed dogs
(70–85%) still die from melanoma. (Prelimi-
nary results of this study indicated a positive
difference in overall survival.)
Magnetic resonance imaging of canine
splenic and liver lesions: The effectiveness of
MRI of the human spleen has been little stud-
ied due to the relative rarity of human splenic
lesions. In dogs, however, splenic lesions are rel-
atively common. Unfortunately, ultrasound, the
cross-sectional imaging modality most readily
available to veterinarians, cannot reliably differ-
entiate benign from malignant splenic and liver
lesions. In this prospective study, Oncology staff
will perform MRI examinations on dogs with
splenic and liver lesions that have been sched-
uled for surgery or biopsies. They seek to deter-
mine the MRI characteristics of these lesions
and to correlate MRI findings with pathologic
examination of the spleen, to better define the
effectiveness of MRI in determining the nature
of splenic and/or liver lesions in both dogs and
people. This study is funded via grants from the
Hospital of the University of Pennsylvania
(Radiology) and Ryan Clinical Research.
Canine lymphoma study: In human medi-
cine, it is well known that lymphoma is not a
solitary disease but a variety of disease, each
involving cancer of lymph cells. Treatment and
outcome are different according to sub-type. It
is also known that treatment of lymphoma
with chemotherapy can effectively wipe out
parts of the immune system for prolonged peri-
ods, which can affect a patient’s ability to fight
off infections and other cancers. This study will
better characterize the sub-types of malignant
lymph cells by flow cytometry and correlate the
results with standard classification schemes and
treatment outcome to establish new prognostic
markers in this disease. Flow cytometry is also
being used to characterize the circulating nor-
mal lymph cells to elucidate the role of the
patients’ immune system in maintaining remis-
sion. Thus, results will help us further under-
stand and eventually better treat this important
and relatively common canine cancer.
Evaluation of the cancer-prevention effects
of non-steroidal drug use in dogs: Results from
human studies show that chronic non-steroidal
anti-inflammatory drugs (NSAID) may prevent
or slow development of various types of cancer.
This preliminary study examines the chemo-
preventive effect of NSAID use in dogs, and
early results indicate that NSAID use may be
associated with decreased cancer risk in dogs.
Feline large granular lymphoma study:
Large granular lymphoma (LGL) is a rare vari-
ant of feline lymphoma. This study aims to
characterize clinical findings for cats diagnosed
with LGL. Results to date show that feline LGL
does not respond well to traditional surgical or
medical treatment, with survival times of only
45 days. Future studies include evaluation of
additional cases, determination of more effec-
tive treatments, and molecular characterization
of feline LGL cell types.
Treatment for canine malignant histiocytosis:
Canine malignant histocytosis/disseminate
histocytic sarcoma is a rare canine cancer with a
grave prognosis. No effect treatment is known.
A preliminary study determined that approxi-
mately 50 percent of diagnosed dogs respond to
the chemotherapeutic agent lomustine. Current
studies are under way to evaluate molecular
mechanisms of drug resistance in tumors that
do not respond to treatment.
These projects vary in scope and size and
affect both animals and humans. The ultimate
goal that underlies each study is finding out
more about cancer—and ultimately about
seeking its cure. In the meantime, while provid-
ing care to thousands of pets with cancer, the
Ryan Oncology team continues to add to the
body of knowledge that enhances our ability to
control this disease, evidence once again that
physicians and veterinarians are truly practicing 
“One Medicine” at Penn.
Editor’s note: For more information, visit
Oncolink, the Internet’s first cancer resource,
sponsored by Penn’s Abramson Cancer Center,
at <www.oncolink.upenn.edu>.
Annual SCAVMA Auction
The Student Chapter of the American
Veterinary Medical Association (SCAVMA)
will be holding its annual auction on Friday,
December 3, 2004, in the E. R. Marookian,
V.M.D. Auditorium at the Matthew J. Ryan
Veterinary Hospital of the University of
Pennsylvania.
Come, bid, and go home with new and
impressive items, ranging from home deco-
rations to exciting vacations. The event
begins with a silent auction at 3:00 p.m., fol-
lowed by a live auction at 5:00 p.m.
SCAVMA will also be selling Penn Veteri-
nary Medicine merchandise while other stu-
dent clubs will provide food and drinks.
Everyone is invited to support the auc-
tion! The SCAVMA auction is a popular
event for the entire School community and
benefits current students. Proceeds from the
silent auction defray the cost of student
travel to the annual National Student AVMA
Symposium. In addition, the live auction
proceeds help fund SCAVMA events and the
SCAVMA Scholarship Program, which
awards scholarships totaling $5,000 to stu-
dents based on their service to the School,
academic standing, and financial need.
The mission of SCAVMA is to increase
the quality of veterinary student life through
educational, social, and cultural extracurricu-
lar activities. Please help support this impor-
tant mission. For more information on the
auction or to donate auction items, contact
Shannon Omlor, V’07, Auction Co-Chairper-
son, via email at somlor@vet.upenn.edu.
